Inotuzumab ozogamicin regulatory update

Pfizer said FDA accepted and granted Priority Review to a BLA for inotuzumab ozogamicin to treat relapsed or refractory B cell precursor acute lymphoblastic leukemia (ALL). Its PDUFA date is in August...